SuperworthProtagonist Therapeutics shares outstanding PTGX
Diluted shares outstanding, averaged over each quarter, from 2015.
- Latest quarter, to Jun 30, 2026
- 71M
- On a year earlier
- +11.8%
- more shares
Protagonist Therapeutics had 71M diluted shares outstanding on average in Q2 FY26, the quarter to Jun 30, 2026.
That is 11.8% more than a year earlier, so each share owns a little less of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2025 | 64M | −4% |
| FY2024 | 66.5M | +10% |
| FY2023 | 60.4M | +23% |
| FY2022 | 49.3M | +2% |
| FY2021 | 48.2M | +22% |
| FY2020 | 39.6M | +43% |
| FY2019 | 27.6M | +14% |
| FY2018 | 24.2M | +20% |
| FY2017 | 20.2M | +21% |
| FY2016 | 16.7M | +6074% |
| FY2015 | 270.8K | n/a |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q2 FY26 | 71M | +12% | |
| Q1 FY26 | 70.5M | +12% | |
| Q4 FY25 | 64M | −4% | |
| Q3 FY25 | 63.8M | +3% | |
| Q2 FY25 | 63.5M | +4% | |
| Q1 FY25 | 63M | −1% | |
| Q4 FY24 | 66.5M | +10% | |
| Q3 FY24 | 61.8M | +4% | |
| Q2 FY24 | 61.3M | +8% | |
| Q1 FY24 | 63.6M | +26% | |
| Q4 FY23 | 60.4M | +23% | |
| Q3 FY23 | 59.2M | +21% |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on Protagonist Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.